Melphalan Flufenamide Hydrochloride Patent Expiration

Melphalan Flufenamide Hydrochloride is used for treating relapsed or refractory multiple myeloma in adults who have received at least 4 prior lines of therapy. It was first introduced by Oncopeptides Ab in its drug Pepaxto on Feb 26, 2021.


Melphalan Flufenamide Hydrochloride Patents

Given below is the list of patents protecting Melphalan Flufenamide Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Pepaxto US10285946 Lyophilized preparations of melphalan flufenamide Apr 25, 2032 Oncopeptides Ab
Pepaxto US10322182 Lyophilized preparation of cytotoxic dipeptides Apr 25, 2032 Oncopeptides Ab
Pepaxto US10543274 Lyophilized preparation of cytotoxic dipeptides Apr 25, 2032 Oncopeptides Ab
Pepaxto US10869928 Lyophilized preparation of cytotoxic dipeptides Apr 25, 2032 Oncopeptides Ab
Pepaxto US11344622 Lyophilized preparation of cytotoxic dipeptides Apr 25, 2032 Oncopeptides Ab
Pepaxto US6992207 Melphalan derivatives and their use as cancer chemotherapeutic drugs Jun 25, 2024

(Expired)

Oncopeptides Ab


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳